A study published in the British Journal of Pharmacology on 3 March, led by University of Queensland researchers Associate Professor Trent Woodruff and Dr John Lee, has found the drug “PMX205” extends the life of mice that have a SOD1 mutation, when administered before or during very early disease onset. More studies are now underway to determine the safety of PMX205 before it can be tested in humans. 'Pharmacological inhibition of complement C5a-C5a1 receptor signalling ameliorates disease pathology in the hSOD1G93A mouse model of amyotrophic lateral sclerosis' tttp://onlinelibrary.wiley.com/doi/10.1111/bph.13730/full
Postive results for PMX205 in mice with SOD1 mutation
Latest News
Community Fundraising Champions – Jo Moroney
Since 2015, Jo Moroney has been hosting the Dale’s Day cricket match in honour of her son Dale Kenny. Sadly, Dale was diagnosed with MND when he was j...
Hadrian’s Wall Walk for MND NSW – 135 kilometres in 6 days
Bev and Steven recently set off on an epic trek along Hadrian's Wall in support of MND NSW. Thank you for your amazing fundraising efforts, and for sh...
MND NSW Winter Appeal 2025 - A Letter from Nick
In early 2025, Anna said goodbye to her husband Nick, following his brave battle against MND. Anna and Nick shared many happy times together, but as h...
A day in the life of an MND carer: What you've told us
Between January and March 2025, we connected with carers who are part of the MND NSW Carer Program. We spoke directly to 84% of carers in the program....